9.09 USD
↗ 0.01 (0.08%)PRE MARKET (AS OF 07:35 AM EDT)
Xeris Biopharma Holdings, Inc. Common Stock
XERSNASDAQ • USD
Market: OPEN
Xeris Biopharma Holdings, Inc. Common Stock (XERS) trades at $9.09 per share. There is a divergence between signals — technical indicators rate "Strong Buy" but underlying fundamentals lean "Sell". This is driven by a concerning Altman Z-Score in the distress zone, exceptional Return on Equity (176.3%), a bullish Golden Cross on the moving averages and bullish moving average alignment. On valuation, XERS trades roughly in line with sector averages — neither particularly cheap nor expensive.
Technical & fundamental data as of Oct 2, 2026.
Open?$9.17
High?$9.17
Low?$9.06
Prev. Close?$9.08
Volume?1.1K
Avg. Volume?2.6M
VWAP?$9.10
Rel. Volume?0.00x
Bid / Ask
Bid?$7.92 × 100
Ask?$10.53 × 100
Spread?$2.61
Midpoint?$9.23
Valuation & Ratios
Market Cap?1.7B
Shares Out?182.3M
Float?176.1M
Float %?96.6%
P/E Ratio?N/A
P/B Ratio?-170.07
EPS?-$0.09
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Employees
435
Market Cap
1.7B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2018-06-21
Address
1375 WEST FULTON STREET, SUITE 1300
CHICAGO, IL 60607
Phone: 844-445-5704
CHICAGO, IL 60607
Phone: 844-445-5704
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?23
Z-Score?17
Momentum?75
Short Sent.?69
Piotroski F-Score?3/9Weak
Altman Z-Score?1.33Distress
Confidence?59%Low
Short InterestModerate
Short % of Float?4.58%Low
Short Interest?8.1M
Days to Cover?4.8
Free Float176.1M
Avg Daily Volume1.7M
Settlement Date2026-09-15
Financial Health
Current Ratio?1.45Adequate
Quick Ratio?1.02Adequate
Cash Ratio?0.64Adequate
Debt/Equity?-25.95Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?-170.07CHEAP▾
S&P97
P/S?4.94FAIR▾
Peers100
S&P29
P/FCF?29.7FAIR▾
Peers100
S&P29
EV/EBITDA?36.6HIGH▾
Peers100
S&P7
EV/Sales?5.33FAIR▾
Peers100
S&P33
Returns & Efficiency
ROE?176.3%STRONG▾
Peers50
S&P97
ROA?-4.2%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$55.7M
Enterprise Value?$1.8B
Fundamentals ratios updated end of day